JLPC(600513)2024-10-29 09:15Financial Performance - The company's operating revenue for Q3 2024 was ¥518,238,697.26, representing a decrease of 1.99% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥29,811,259.47, an increase of 9.14% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,360,487.06, up by 7.89% compared to the previous year[2]. - The net profit for Q3 2024 was CNY 107,539,004.59, an increase of 6.9% compared to CNY 100,597,014.28 in Q3 2023[12]. - The total comprehensive income for Q3 2024 was CNY 107,465,954.63, compared to CNY 100,597,014.28 in Q3 2023[13]. - The basic earnings per share for Q3 2024 was CNY 0.32, up from CNY 0.31 in Q3 2023[13]. Assets and Liabilities - The total assets at the end of Q3 2024 reached ¥3,030,586,462.79, reflecting a growth of 6.12% from the end of the previous year[2]. - Total assets as of September 30, 2024, amounted to RMB 3,030,586,462.79, up from RMB 2,855,702,313.77 at the end of 2023, reflecting a growth of 6.13%[9]. - The total liabilities as of September 30, 2024, were RMB 1,452,398,685.36, compared to RMB 1,338,392,050.47 at the end of 2023, reflecting an increase of 8.52%[10]. - Current assets totaled RMB 1,384,873,898.48, slightly increasing from RMB 1,353,403,011.17 at the end of 2023, indicating a growth of 2.33%[9]. - Short-term borrowings rose to RMB 706,935,687.52, compared to RMB 591,762,392.08 at the end of 2023, marking an increase of 19.43%[10]. - Long-term equity investments decreased to RMB 7,023,341.85 from RMB 11,636,901.86, a decline of 39.81%[9]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥24,044,102.97, showing a significant increase of 325.87% year-on-year due to higher sales collections[4]. - Operating cash flow for the first three quarters of 2024 was CNY 24,044,102.97, a significant improvement from a negative cash flow of CNY -10,645,088.02 in the first three quarters of 2023[15]. - The net cash flow from financing activities was CNY 52,992,683.56, a significant increase from CNY 8,709,722.97 in the previous year[16]. - The total cash outflow from financing activities amounted to CNY 480,020,125.74, compared to CNY 440,980,277.03 in the same period last year[16]. - The cash and cash equivalents at the end of the period were CNY 191,411,578.34, an increase from CNY 175,832,532.70 year-over-year[16]. - The net increase in cash and cash equivalents was CNY -58,778,444.23, an improvement from CNY -133,215,221.67 in the previous year[16]. Shareholder Information - The company reported a total of 28,117 common shareholders at the end of the reporting period[4]. - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., held 39.90% of the shares, totaling 113,884,816 shares[4]. Research and Development - Research and development expenses rose to CNY 94,317,179.81, up 36.7% from CNY 69,041,803.18 in the same period last year[12]. - The company reported a significant increase in development expenditures to RMB 130,961,502.79 from RMB 37,652,025.61, indicating a focus on new product and technology development[9]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth and profitability[12].